

Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

November 12, 2025

BSE Limited National Stock Exchange of India Limited

P. J. Towers, Exchange Plaza, Plot No. C/1,
Dalal Street, G Block, Bandra-Kurla Complex,
Mumbai- 400 001 Bandra (E) Mumbai- 400 051

Scrip Code-540025 Trading Symbol-ADVENZYMES

Subject: Press Release

Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated November 12, 2025.

This is for your information and for public at large.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

Sanjay Basantani Company Secretary and Head – Legal

Encl.: As above



FOR IMMEDIATE RELEASE

QUARTERLY EARNINGS RELEASE

Thane, India: Wednesday, November 12, 2025

Advanced Enzyme Technologies Limited announces Financial Results for Second Quarter and Half Year ended September 2025

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for second guarter and half year ended September 2025.

CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

| (Amount in INR Mn.) | Q2 FY26 | Q1 FY26 | Q2 FY25 | Change (Y-o-Y %) | Change (Q-o-Q %) | H1 FY26 | H1 FY25 | Change (%) |
|---------------------|------------|------------|------------|---------------------|---------------------|---------|---------|---------------|
| Revenue | 1,845 | 1,859 | 1,461 | +26% | -1% | 3,704 | 3,006 | +23% |
| EBITDA | 601 | 564 | 424 | +42% | +6% | 1,165 | 936 | +24% |
| EBITDA Margin (%) | 33% | 30% | 29% | | | 31% | 31% | |
| PAT | 447 | 404 | 334 | +34% | +11% | 852 | 684 | +25% |
| PAT Margin (%) | 24% | 22% | 23% | | | 23% | 23% | |
| EPS | 3.87 | 3.57 | 2.94 | +32% | +9% | 7.44 | 5.99 | +24% |

CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to $\stackrel{?}{\stackrel{?}{\sim}}$ 1,845 million in the Q2 FY26 from $\stackrel{?}{\stackrel{?}{\sim}}$ 1,461 million in the Q2 FY25, a growth of 26%.

Profit:

Consolidated EBITDA during Q2 FY26 stands at ₹ 601 million as compared to ₹ 424 million during Q2 FY25, an increase of 42%.

Profit before tax stands at ₹ 595 million during Q2 FY26 as against ₹ 422 million in Q2 FY25, an increase of 41%.

Profit after tax grew by 34% and stands at ₹ 447 million during Q2 FY26 as compared to ₹ 334 million during the Q2 FY25.

Margin:

EBITDA margin stands at 33%, PBT margin stands at 32% and PAT margin stands at 24% during the quarter.

Financial Costs:

Financial costs stood at ₹ 7 million during Q2 FY26 as against ₹ 9 million in Q2 FY25.

Depreciation and Amortization:

Depreciation and Amortization charge for the Q2 FY26 stood at ₹ 101 million as compared to ₹ 89 million in the same quarter previous year.

Earnings Per Share:


Earnings Per Share during Q2 FY26 stands at ₹ 3.87 as compared to ₹ 2.94 in Q2 FY25.



OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

| (Amount in INR Mn.) | Q2 FY26 | Q2 FY25 | Change (%) |
|---------------------------|------------|------------|---------------|
| Human Nutrition | 1,212 | 992 | +22% |
| Animal Nutrition | 193 | 181 | +6% |
| Bio-Processing | 255 | 168 | +52% |
| Specialized Manufacturing | 185 | 120 | +54% |



The total revenue from operations grew by 26% on y-o-y basis and declined by 1% on q-o-q basis.


Revenue from the Human Nutrition segment increased by 22%, reaching ₹1,221 million in Q2 FY26, compared to ₹992 million in Q2 FY25. This growth was driven by higher sales in the Pharma/API and Nutrition businesses across both domestic and international markets.

The Animal nutrition delivered a growth of 6% to ₹ 193 million in Q2 FY26 as against ₹ 181 million in Q2 FY25.

The Bio-Processing segment recorded strong growth of 52% during the quarter, reaching ₹255 million in Q2 FY26, compared to ₹168 million in Q2 FY25. This growth was primarily driven by the Food business, which surged 77% y-o-y to ₹206 million in Q2 FY26. In contrast, the Non-Food business declined by 4%, standing at ₹49 million for the quarter.

The Specialized Manufacturing segment contributed 10% to the total revenue, amounting to ₹185 million during the quarter, reflecting a y-o-y growth of 54%.

Geographical Revenue:



Domestic sales accounted for ₹887 million in Q2 FY26 as compared to ₹703 million in Q2 FY25, higher by 26%.

The total revenue includes international sales of ₹958 million in Q2 FY26, compared to ₹758 million in Q2 FY25, representing a y-o-y increase of 26%. The revenue declined by 3% in the Americas, while Europe and Asia (ex-India) recorded robust growth of 114% and 153%, respectively. Revenue from the rest of the world increased marginally by 1%.

During Q2 FY26, domestic sales accounted for 48% and international sales for 52% of revenue from operations, maintaining the same fraction as in Q2 FY25.



CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

Revenue from Operations:

Revenue from operations on consolidated basis decreased to ₹ 1,845 million in the Q2 FY26 from ₹ 1,859 million in the Q1 FY26, a de-growth of 1%.

Profit:

Consolidated EBITDA during Q2 FY26 stands at ₹ 601 million as compared to ₹ 564 million during Q1 FY26, higher by 6%.

Profit before tax stands at ₹ 595 million during Q2 FY26 as against ₹ 549 million in Q1 FY26, an increase of 8%

Profit after tax grew by 11% and stands at ₹ 447 million during Q2 FY26 as compared to

₹ 404 million during the Q1 FY26.

Financial Costs:

Financial costs stood at ₹ 7 million during Q2 FY26 as against ₹ 8 million in Q1 FY26.

Depreciation and Amortization:

Depreciation and Amortization charge for the Q2 FY26 is ₹ 101 million as compared to ₹ 96 million in the last quarter.

Earnings Per Share:

Earnings Per Share during Q2 FY26 stands at ₹ 3.87 as compared to ₹ 3.57 in Q1 FY26.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

| (Amount in INR Mn.) | Q2 FY26 | Q1 FY26 | Change (%) |
|---------------------------|------------|------------|---------------|
| Human Nutrition | 1,212 | 1,221 | -1% |
| Animal Nutrition | 193 | 260 | -26% |
| Bio-Processing | 255 | 236 | 8% |
| Specialized Manufacturing | 185 | 142 | 30% |

The human nutrition segment marginally de-grew by 1% to ₹ 1,212 million in Q2 FY26 as compared to ₹ 1,221 million in Q1 FY26.

The Animal nutrition business declined by 26% to

Geographical Revenue:

Domestic Sales amounted to ₹887 million in Q2 FY26, compared to ₹979 million in Q1 FY26, reflecting a sequential decline of 9%. Domestic sales accounted for approximately 48% of total revenue from operations, compared to 53% in Q1 FY26.

International Sales demonstrated strong growth, reaching ₹958 million in Q2 FY26, up from ₹881

₹ 193 million in Q2 FY26 as against ₹ 260 million in Q1 FY26.

The Bio-Processing segment recorded an 8% sequential growth, generating ₹255 million in Q2 FY26 compared to ₹236 million in Q1 FY26. Within this segment, the Food business grew by 18% to ₹206 million, while the Non-Food business declined by 20% to ₹49 million, compared to the previous guarter.

The Specialized Manufacturing segment delivered a strong growth of 30%, reaching ₹185 million in Q2 FY26, up from ₹142 million in Q1 FY26.

million in Q1 FY26, a 9% increase. The revenue grew by 26% in Europe and 45% in Asia (ex-India), while the Americas and the rest of the world recorded a modest decline of 2% and 32%, respectively. International sales now represent 52% of total revenue from operations, up from 47% in Q1 FY26.



CONSOLIDATED HALF YEARLY FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to \gtrless 3,704 million in the H1 FY26 from \gtrless 3,006 million in the H1 FY25, reported higher by 23%.

Profit:

Consolidated EBITDA during H1 FY26 stands at ₹ 1,165 million as compared to ₹ 936 million during H1 FY25, growth of 24%.

Profit before tax stands at ₹ 1,144 million during H1 FY26 as against ₹ 909 million in H1 FY25, an increase of 26%.

Profit after tax stands at ₹ 852 million during H1 FY26 as compared to ₹ 684 million during the H1 FY25, an increase of 25%.

Margin:

EBITDA margin stands at 31%, PBT margin stands at 31% and PAT margin stands at 23% during the H1 FY26.

Financial Costs:

Financial costs stood at ₹ 15 million during H1 FY26 as against ₹ 18 million in H1 FY25.

Depreciation and Amortization:

Depreciation and Amortization charge for the H1 FY26 is ₹ 197 million as compared to ₹ 175 million in H1 FY25.

Earnings Per Share:

Earnings Per Share during H1 FY26 stands at ₹7.44 as compared to ₹5.99 in H1 FY25.

OPERATIONAL PERFORMANCE REVIEW:


Segmental Revenue:

| (Amount in INR Mn.) | H1 FY26 | H1 FY25 | Change (%) |
|---------------------------|------------|------------|---------------|
| Human Nutrition | 2,434 | 2,003 | +21% |
| Animal Nutrition | 452 | 353 | +28% |
| Bio-Processing | 491 | 419 | +17% |
| Specialized Manufacturing | 327 | 230 | +42% |

The Human Nutrition segment delivered strong outperformance of 21%, reaching ₹2,434 million in H1 FY26, compared to ₹2,003 million in H1 FY25.

The Animal Nutrition segment also demonstrated robust growth, increasing by 28% to ₹452 million in H1 FY26, up from ₹353 million in H1 FY25.

The Bio-Processing segment grew by 17% during the first half, contributing ₹491 million in H1 FY26, compared to ₹419 million in H1 FY25. Within this segment, the Food business accounted for 10% of




total revenue, reaching ₹380 million, delivering 22% growth, while the Non-Food business contributed 3%, amounting to ₹111 million, with 4% growth.

The Specialized Manufacturing segment contributed 9% to the total revenue, growing impressively by 42% YTD, reaching ₹327 million in H1 FY26.



Geographical Revenue:



International Sales contributed ₹1,839 million in H1 FY26, compared to ₹1,564 million in H1 FY25,

reflecting a strong growth of 18% y-o-y. The revenue declined by 4% in the Americas, while registering robust growth of 61% in Europe, 104% in Asia (ex-India), and 30% in the rest of the world

Domestic Sales amounted to ₹1,866 million in H1 FY26, compared to ₹1,442 million in H1 FY25, representing a 29% y-o-y increase. Domestic sales contributed approximately 50% of total revenue from operations, up from 48% in H1 FY25, while international sales accounted for the remaining 50%, slightly lower than 52% in H1 FY25.



OUTLOOK 2025-26

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

Human Nutrition:

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

Animal Nutrition:

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

Probiotics:

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal

Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

Bio Catalysis:

The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

Baking:

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

Research & Development:

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

Inorganic expansion:

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its frontend marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.



RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 13th November 2025, Thursday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, <u>www.advancedenzymes.com</u>

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: + 91 86 3416 8438 / +91 86 4536 7185

Pre-registration link

For further information, please contact:

Ronak Saraf

Investor Relations

CORPORATE INFORMATION:

Advanced Enzyme Technologies Limited Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica, Louiswadi, Thane (W) -400 604,

Maharashtra, India Tel.: +91 22 41703200 Fax: +91-22 25835159

Website: www.advancedenzymes.com CIN No: L24200MH1989PLC051018